A Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids, in Subjects With Non-ambulatory Duchenne Muscular Dystrophy (DMD)
Abstract
To evaluate the efficacy and safety of pamrevlumab versus placebo in combination with
systemic corticosteroids in subjects with non-ambulatory Duchenne muscular dystrophy (age 12
years and older).